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Environmental factors contribute to Type 1 diabetes (T1D) susceptibility. The gut
microbiome, which includes bacteria, viruses, and fungi, contributes to this environmental
influence, and can induce immunological changes. The gut viral component of the
microbiome, related to T1D has mostly focused on coxsackieviruses and rotavirus.
The role of norovirus, another common enteric virus, in susceptibility to T1D was
hitherto unknown. Norovirus is highly infectious and encountered by many children. We
studied the mouse norovirus 4 (MNV4), related to human noroviruses, in the Non-obese
diabetic (NOD) mouse model, to determine its role in influencing susceptibility to T1D.
We infected MNV-free NOD mice with MNV4 by exposing the mice to MNV4-positive
bedding from an endemically-infected mouse colony to mimic a natural infection.
Control MNV-free NOD mice were exposed to MNV-free bedding from the same colony.
Interestingly, MNV4 infection protected NOD mice from the development of T1D and
was associated with an expansion of Tregs and reduced proinflammatory T cells.
We also found MNV4 significantly modified the gut commensal bacteria composition,
promoting increased α-diversity and Firmicutes/Bacteroidetes ratio. To elucidate whether
T1D protection was directly related to MNV4, or indirectly through modulating gut
microbiota, we colonized germ-free (GF) NOD mice with the MNV4-containing or
non-MNV4-containing viral filtrate, isolated from filtered fecal material. We found that
MNV4 induced significant changes in mucosal immunity, including altered Tuft cell
markers, cytokine secretion, antiviral immune signaling markers, and the concentration
of mucosal antibodies. Systemically, MNV4-infection altered the immune cells including
B cell subsets, macrophages and T cells, and especially induced an increase in Treg
number and function. Furthermore, in vitro primary exposure of the norovirus filtrate
to naïve splenocytes identified significant increases in the proportion of activated and
CTLA4-expressing Tregs. Our data provide novel knowledge that norovirus can protect
NOD mice from T1D development by inducing the expansion of Tregs and reducing
inflammatory T cells. Our study also highlights the importance of distinguishing the
mucosal immunity mediated by bacteria from that by enteric viruses.
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INTRODUCTION
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease
resulting from the destruction of insulin-producing pancreatic
β-cells. The incidence of T1D is increasing worldwide, at a rate
too fast to be associated with genetic changes alone. Increasing
evidence suggests that environmental factors can contribute to
the risk of T1D development. Studies in both animal models and
humans have identified changes in the bacterial component of the
gut microbiota composition in individuals with T1D or “at-risk”
compared to controls (1–11). In addition, enteric viruses, such as
the Coxsackieviruses and Rotavirus have been associated with the
development of T1D in both humans andmouse models (12–21).
Interestingly, a coxsackievirus B vaccine has shown to protect
Non-obese Diabetic (NOD) mice from the development of virus-
induced diabetes (22) and a recent human study suggests that
rotavirus vaccination of infants has contributed to the decreased
incidence of T1D in Australian children (23). However, little is
known about other viruses including norovirus in relation to
T1D development.
Norovirus, a common enteric virus belonging to the family
Caliciviridae, is highly contagious and responsible for the
majority of non-bacterial gastroenteritis outbreaks, especially in
the winter, and infections have often been referred to by the
non-scientific name “stomach flu” (24). In most individuals,
norovirus infections are short-lived but the infection can
have severe complications in young children, the elderly and
immunocompromised individuals (25–27). Transmission occurs
by the fecal-oral route, either through direct contact with infected
individuals or indirectly through exposure to contaminated food
or water, and by infectious aerosols generated by vomiting
(28–31). Given that the majority of individuals diagnosed with
T1D are children, and the incidence appears to peak in winter
(32) when it is also high season for norovirus infection, it
is extremely important to investigate the role of norovirus in
mediating susceptibility to T1D. It is likely norovirus infection is
an additional stressor of the immune system prior to diagnosis
and is not the cause of T1D, as many people infected with
norovirus do not develop T1D.
Murine norovirus (MNV), a non-enveloped single-stranded
RNA virus related to human noroviruses, is often used to study
the role of norovirus infections in mouse models. MNV was
first described following the investigation of high mortality in
Rag/Stat-1 double-deficient mice (33). MNV has been shown
to alter susceptibility to inflammatory bowel disease (IBD) and
food allergies (34–36), by altering other components of the
gut microbiota composition and gut immunity. Furthermore,
the bacterial components of gut microbiota also affect the
host susceptibility to norovirus infection, supported by the
observation that antibiotic treatment prevented norovirus
persistence due to changing the gut bacterial composition (37).
Thus, MNV can alter both gut microbiota composition and
immune responses of the host.
Our previous studies and those of other investigators have
demonstrated that susceptibility to T1D development in NOD
mice depends on immune signaling in response to themicrobiota
(8, 9, 38–41) and to coxsackievirus (42, 43) or rotavirus (17, 19).
However, it is unknown if MNV alters the susceptibility to
T1D development in NOD mice. We hypothesize that MNV
infection will affect T1D susceptibility in NODmice by changing
gut commensal bacteria and hence local, as well as systemic,
immune responses of the hosts. The current study was to test this
hypothesis and to fill our knowledge gap regarding the role of
norovirus infection in T1D development.
MATERIALS AND METHODS
Mice
Specific pathogen-free (SPF) NOD mice were purchased from
the Jackson Laboratory and housed under SPF conditions in
individually-ventilated filter-topped cages at the Yale Animal
Resource Center (YARC). These mice were reported free
of murine norovirus, ectromelia virus, murine rotavirus,
lymphocytic choriomeningitis virus, mouse hepatitis virus,
mouse parvovirus, minute virus of mice, pneumonia virus
of mice, reovirus, Sendai virus, Mycoplasma pulmonis,
Helicobacter spp., pinworms, fur mites, and opportunistic
bacteria (https://www.jax.org/strain/001976). Germ-free (GF)
NOD mouse breeders were generously provided by Alexander
Chervonsky (University of Chicago, USA) and have been
bred and maintained at the gnotobiotic facility of YARC. All
the mice received autoclaved food (Global 2018S, Envigo)
and hyperchlorinated (4–6 ppm) water ad libitum and were
maintained on 12-h light/dark cycles. The use of mice in this
study was approved by the Institutional Animal Care and Use
Committee at Yale University.
MNV Detection and Infection
The SPF mouse housing room in which this study was conducted
was screened for MNV infection by PCR of fecal samples.
Fecal pellets were homogenized in PBS and DNA was isolated
using a DNeasy kit (Qiagen) according to the manufacturer’s
instructions. PCR amplification was performed using a PCRCore
kit (Roche) and primers specific for the MNV non-structural
gene (see Supplementary Table 1). The strain of MNV identified
by sequencing was consistent with MNV4. The MNV4-positive
cage bedding was collected and introduced to the cages that
housed MNV-free NOD mice (4–5 week of age). The cages
had half the bedding replaced with autoclaved clean bedding,
weekly. As a control, another set of MNV-free NOD mice were
introduced to MNV-free bedding from different cages within the
same housing room. To avoid cross-contamination, the control
NOD mice were housed in a different room in the same facility.
All the mice were screened by PCR for the presence of MNV4
in the fecal material and by an immuno-fluorescence assay for
the presence of anti-MNV antibodies in the serum. Briefly,
microscope slides were mounted with monolayers of MNV-
infected RAW 264.7 cells, a mouse macrophage cell line. Serum
samples (1:10 dilution) were added to the slides and the binding
of MNV antibodies was detected with fluorescein-conjugated
goat anti-mouse antisera. All MNV+ mice continued to actively
shed virus throughout the study. Only mice exposed to MNV
had anti-MNV antibodies in the serum. All control (MNV4-free)
mice remained free of MNV infection.
Frontiers in Immunology | www.frontiersin.org 2 November 2019 | Volume 10 | Article 2654
Pearson et al. Norovirus Infection Protects T1D Development
Diabetes Incidence
MNV-infected and control NOD mice were monitored for
glycosuria weekly, for 25 weeks. Glycosuria was confirmed by
two blood glucose measurements, 24-h apart, of over 250 mg/dl
(>13.9 mmol/L).
Histology
Pancreata from 12-week old MNV-free (control) and MNV-
infected NOD female mice were formalin-fixed and embedded
in paraffin. Tissues were stained with hematoxylin and eosin.
Insulitis was scored under light microscopy. 150–200 islets from
4 to 5 mice were individually scored.
16s rRNA Sequencing of Gut Microbiota
Fecal samples were collected from MNV-free (control) and
MNV-infected mice and resuspended in 300 µl TE buffer
containing 0.5% SDS and 200µg/ml Proteinase K. Bacterial DNA
was extracted as previously described (44). The V4 region of
the 16S rRNA gene was amplified from each DNA sample using
a bar-coded, broadly conserved, bacterial forward, and reverse
primer as previously published (8). Bacterial DNA samples were
used for pyrosequencing with Ion Torrent PGM sequencing
system (Life Technologies). The results were analyzed using
QIIME 1.8. α-diversity, a measure of the number of bacteria,
and β-diversity, a measure of the composition of the microbiota
were both analyzed and β-diversity was plotted using a principal
coordinate analysis (PCoA) plot.
Flow Cytometry and Intracellular Staining
Immune cells were incubated with an Fc-blocking antibody
at 4◦C for 15min. Post-incubation, cells were stained for
surface markers using antibodies (conjugated with different
fluorochrome) against CD4, CD8, CD11b, CD11c, CD19, CD21,
CD23, CD39, CD69, CD86, CTLA4, CXCR3, KLRG1, TCRbeta,
IgA, IgD, IgM, CCR6, CCR7, CCR9, and a viability dye (all from
BioLegend), for 30min at 4◦C. For Treg staining, cells were
stained for surface markers prior to fixation for 1 h at room
temperature and subsequent permeabilization (buffers purchased
from Tonbo Bioscience). The cells were then incubated with
an Fc-blocking antibody at 4◦C for 15min prior to staining
with anti-FoxP3 (eBioscience), incubated for 30min, at 4◦C;
following by washing. For intracellular cytokine staining, cells
were incubated at 37◦C in the presence of PMA (Sigma),
Ionomycin (Sigma) and Golgi Plug (BD) for 4 h prior to washing
and surface staining as outlined above. After surface staining,
cells were fixed (20min, room temperature) and permeabilized
(buffers purchased from Sigma) and incubated with an Fc-
blocking antibody at 4◦C for 15min prior to staining with
anti-cytokine antibodies (30min, 4◦C) and washing. Cells were
analyzed on a BD LSR II flow cytometry followed by analysis
using Flowjo software.
Infection of Germ-Free NOD Mice
Fecal pellets were pooled from 6 individual 12-week old MNV4+
donors and resuspended in sterile PBS. Pellets were homogenized
using a bead beater machine and large fecal materials were
removed by centrifugation (500 rpm, 3min). Supernatant was
further centrifuged at high speed (13,000 rpm, 5min) followed
by filtration through a 0.22µM filter (Millipore). This filtered
supernatant was then divided into two portions, with half of
the solution exposed to UV light (20min, room temperature) to
destroy the virus (virus –) and the other half left unexposed to
UV light (virus +). GF NOD mice (∼4 weeks-old) were gavaged
with 200 µl of the UV-treated or non-UV treated solution.
GF NOD mice were regularly assessed for viral presence in
the fecal sample and antibodies in the serum, before and after
inoculation, as described earlier. Mice were terminated 8-weeks
after gavage for the study and the experimental design is shown
in Supplementary Figure 1.
qPCR
RNA was extracted from the distal small intestine of colonized
GF NOD mice, using a Qiagen RNAeasy kit, prior to cDNA
synthesis following the manufacturer’s instructions (Bio-Rad).
qPCR was performed using a qPCR cycler (iQ5; Bio-Rad
Laboratories), according to the manufacturer’s instructions with
the specific primers listed in Supplementary Table 1. The relative
gene expression was determined using the 2−11CT method by
normalization with GAPDH housekeeping gene.
Antibody Measurements
Serum and cecal wash were collected from the mice studied
at termination. Antibody concentrations were determined by
ELISA, using the reagents purchased from Southern Biotech,
following the protocol previously described (8). Samples were
diluted (serum 1:50–1:100; cecal samples 1:2–1:10) before
the antibody measurements. Antibody concentrations were
converted based on each of the standard curves.
Treg Suppression Assay
Treg cells were purified from spleen of colonized GF NOD
mice using magnetic bead isolation kits (EasySep TM
Mouse CD4+CD25+ Regulatory T cell isolation kit, Stemcell
Technologies). BDC2.5 CD4T cells were isolated from BDC2.5 T
cell receptor (TCR) transgenic NOD mice by negative selection
using hybridoma supernatants to deplete MHCII+ (10.12.16)
antigen presenting cells (APCs) and CD8T cells (TB105).
Hybridoma supernatants were kindly provided by the late
Charles Janeway Jr. (Yale University). Isolated Tregs were
co-cultured with BDC2.5 CD4T cells in a 1:2 (Treg:Teff) ratio
in the presence of irradiated APCs and different concentrations
of BDC2.5 mimotope peptide. The cells were cultured for 4
days prior to pulsing with 3H-thymidine, for a further 18 h. Data
were presented as corrected counts per minute (1cpm) after
subtracting from background (Tregs + BDC2.5 CD4T cells
without antigenic peptide).
In vitro Culture
Splenocytes from colonized GF NOD mice (2 × 106) were
cultured in the presence or absence of non-UV treated (MNV4-
containing) fecal material, prepared as described above. Cells
were stimulated for 16 h with the final 4 h in the presence of
PMA, Ionomycin (both Sigma) and Golgi Plug (BD), prior to
surface and intracellular staining as outlined above. Another set
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of cells was stimulated for 16 h with UV-treated and non-UV
treated (MNV4-containing) fecal material for RNA isolation after
removing the stimulators. The cultured cells were also used for T
cell and APC isolation by negative selection using monoclonal
antibody supernatants. For T cell isolation, 10.2.16, HB198 and
N418 were used to remove MHC II+ cells by magnetic beads.
For APC isolation, Y19 was used to remove Thy1+ T cells by
complement. All the mAb supernatants were provided by the late
Charles Janeway Jr. (Yale University).
Adoptive Transfer
Splenocytes were cultured for 12 h, in the presence or
absence of non-UV treated (MNV4-containing) fecal material,
prepared as described above. After thorough washing, the
stimulated splenocytes were adoptively transferred into Rag-
deficient NOD mice (4 × 106/donor). Tissues were harvested 1
week post-transfer.
RESULTS
MNV4 Infection Protects NOD Mice From
the Development of Type 1 Diabetes
To determine whether norovirus can alter the susceptibility
of NOD mice to development of type 1 diabetes, MNV-free
NOD mice were exposed at 4–5-weeks of age to bedding
from either MNV- or MNV+ cages, of mice housed in the
same facility. All MNV-infected mice were confirmed as virus
positive by PCR in fecal samples, 2-weeks post-exposure, and
the majority of the mice continued to shed virus throughout the
study. All non-infected control mice remained virus-free. The
mice from 10-weeks of age were tested weekly for glycosuria
and followed longitudinally to determine the incidence of
spontaneous diabetes in norovirus-infected and control mice.
We found that norovirus exposure significantly delayed and
reduced the incidence of diabetes development, compared to the
control mice, by 25-weeks of age (Figure 1A). The delay was
more striking at 14–20 weeks of age when only∼30% of infected
mice developed diabetes by 20 weeks, compared to over 85%
of control mice (p = 0.006). To determine, whether norovirus
infection also reduced the immune cell infiltration in the
pancreatic islets, pancreata from 12-week old pre-diabetic mice
were studied for the severity of islet infiltration. In agreement
with the diabetes incidence, we found norovirus-infected mice
also had less insulitis compared to norovirus-free control NOD
mice (Figure 1B).
MNV4 Infection Promotes the Expansion of
Regulatory T Cells and Reduces
Inflammatory Cytokines and T Cell
Activation
As β-cell damage in T1D is an immune-mediated process
we investigated changes of the immune system that could
contribute to diabetes protection, in response to norovirus
infection. We demonstrated that norovirus infection specifically
enhanced the total number and proportion of regulatory
T cells in the pancreatic draining lymph nodes (PLN)
compared to uninfected control mice (Figures 2A,B and
Supplementary Figure 2). We also evaluated the cytokine
secretion profile from CD4T cells and our results showed a
significant reduction in IFNγ-secreting CD4T cells, specifically
in the PLN and Peyer’s patches (PP), while the proportion
of IL-10, TNFα, or IL-17a-secreting CD4T cells remained
unchanged (Figure 2C and Supplementary Figures 3A–D).
Whilst we found no differences in CD4T cell activation (CD69,
Supplementary Figure 3E), we observed a significant reduction
in CD8T cell activation, particularly in the PLN (Figure 2D
and Supplementary Figure 3F). We found no significant
differences in IFNγ, TNFα, or IL-10 secretion from CD8T cells
(Supplementary Figures 3G–I). We also assessed changes in
B cells, macrophages and dendritic cells in different lymphoid
tissues and did not observe significant differences between the
two groups (Supplementary Figure 4). Thus, the protection in
FIGURE 1 | Norovirus infection protects NOD mice from the development of T1D. (A) Diabetes incidence was observed in MNV-infected (norovirus group) or
MNV-negative (control) NOD mice, n = 13–15. Mice were monitored for glycosuria weekly for 25 weeks. Diabetes was confirmed by 2 blood glucose measurements,
24-h apart, of over 250 mg/dl (13.9 mmol/L). (B) 12-week old NOD mice infected or free of norovirus were harvested for their pancreata and assessed for insulitis by
light microscopy, n = 5–6. Islets were graded using the following scale: 1: No insulitis, 2: >25% insulitis, 3: 25–50% insulitis, 4: >50% insulitis. Data were analyzed for
significance using a log-rank test for survival at 20 and 25 weeks of age (A) or a chi-square test (B). *P < 0.05, **P < 0.01, ***P < 0.001. Data are representative of
one of two experiments.
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FIGURE 2 | Norovirus infection expands Tregs and reduces inflammatory T cells. The number (A) and proportion (B) of CD4+FoxP3+ T cells were investigated from
the spleen, pancreatic lymph node (PLN), mesenteric lymph node (MLN), and Peyer’s patches (PP) of norovirus-free and norovirus-infected NOD mice. Tregs were
gated on live single TCRbeta+CD4+CD8- T cells prior to FoxP3 gating. (C) Cells were stimulated for 4-h in the presence of PMA, Ionomycin, and Golgi Plug prior to
surface and intracellular staining. IFNγ-secreting CD4T cells were gated from live, single TCRbeta+CD4+CD8- T cells prior to gating on IFNγ. (D) The proportion of
CD69+ CD8T cells gated from live single TCRbeta+CD8+CD4- T cells prior to gating on CD69. Data were analyzed for significance using a Student’s T-test. *P <
0.05, ***P < 0.001. Data represents pooled data from two independent experiments; n = 9–11 mice.
the NOD mice infected with norovirus was associated with the
expansion of Tregs and reduction of IFNγ-producing CD4T
cells and activation of CD8 T cells.
MNV4 Infection Alters the Composition of
Gut Commensal Bacteria
Our previous studies and those of others have shown that the
changes in composition of gut commensal bacteria influence
susceptibility to T1D in both NOD mice and humans (1, 3, 6,
8, 9, 11, 45). As norovirus is an intestinal virus and can alter
the overall gut commensal bacteria composition in IBD (35), we
investigated whether gut commensal bacterial composition was
altered in MNV4-infected mice by 16S rRNA sequencing. We
found that norovirus infection increased the intestinal microbial
α-diversity and Firmicutes/Bacteroidetes ratio compared to
the control mice that are more susceptible to diabetes
(Figures 3A,B). Both of these changes have been reported to
be associated with protection from the development of T1D
in humans (1). To determine whether gut commensal bacterial
composition was significantly different between uninfected
control mice and norovirus-infected NOD mice, we conducted
a principal component analysis of β-diversity. Our results
revealed that the presence of norovirus significantly altered
the composition of gut commensal bacteria (Figure 3C).
Furthermore, we found significant increases in the relative
abundance of Akkermansia muciniphilia and non-identifiable
species of Ruminococcus,Mogibacteriaceae, Lachnospiraceae, and
Anaerostipes in uninfected NOD mice compared to norovirus-
infected NOD mice (Figure 3D). However, norovirus-infected
mice had increased relative abundances of RF32, Mucispirillum
schaedleri and YS2 species compared to uninfected control mice.
Together, our data demonstrate that MNV4 infection can alter
the composition of gut commensal bacteria in NOD mice,
suggesting a role in diabetes protection in the MNV4-infected
NODmice.
MNV4 Infection of Germ Free (GF) NOD
Mice Significantly Alters Intestinal
Immunity
In the above experiments using SPF NOD mice, we infected
the mice naturally with MNV+ bedding from the cages housing
MNV-infected mice and the control mice had MNV- bedding.
However, it was not clear whether diabetes protection and Treg
cell expansion were the direct effect of norovirus or an indirect
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FIGURE 3 | Norovirus infection alters the gut commensal bacterial composition in NOD mice. Fecal pellets were collected from 12-week old NOD mice that were
MNV-free (control) or MNV-infected (norovirus). (A) α-diversity was assessed using the Shannon diversity index. (B) The Firmicutes/Bacteroidetes ratio were calculated
from the phylogenetic data. (C) β-diversity was investigated using a principal component analysis plot, with significant species differences plotted (D). Data were
assessed for significance using a Student’s T-test (A,B), ANOSIM (C) or multiple T-test and FDR correction (D). *P < 0.05, **P < 0.01, ***P < 0.001. Data shown are
pooled from two experiments (n = 9–11 mice). ND, not detectable.
effect through virally-induced gut commensal bacterial changes.
To elucidate the specific impact of norovirus on the immune
system, we studied Germ-Free (GF) NOD mice. We infected
GF NOD mice with pooled and filtered [removing the bacteria
(46)] donor fecal material from mice infected with MNV4 (see
Material & Methods and Supplementary Figure 1). As a control
we UV-treated the same material to destroy the virus. All control
mice remained negative for MNV4 (virus–) by PCR following
colonization, and also negative for MNV-specific antibodies in
serum, whereas the MNV4 infected mice (virus+) were positive
for both virus in the feces and MNV-specific antibodies in the
serum. Furthermore, we investigated the composition of gut
microbiota from the infected mice but did not find significant
changes between the virus-infected or non-virus-infected group
(Supplementary Figure 5). Thus, the changes observed in the
mice are predominantly associated with the presence/absence
of norovirus.
To investigate the effect of MNV infection on intestinal
immunity, we measured various cytokines in the cecal wash from
virus– and virus+ ex-GF mice. We found significant increases
in the concentration of IFNα, IL-4, IL-10, IL-17a, and IFNγ but
no differences in TGFβ in virus+ mice compared to virus– mice
(Figure 4A). Different MNV strains have different cell tropisms,
and have been shown to infect both immune cells (47, 48)
and specialized intestinal epithelial cells (IECs) called Tuft cells
(49). To determine whether MNV4 were present in IECs, we
isolated the IECs from the small intestine of ex-GF mice and
detected MNV4 by qPCR. We found that the MNV4 gene was
highly expressed in the mice exposed to MNV4 compared to
the uninfected controls (Figure 4B). This suggests that IECs
are most likely a target for MNV4 infection. Next, we assessed
the Tuft cell-related gene expression in the small intestine of
the ex-GF mice by qPCR, given MNV1 has been reported
to infect Tuft cells (49). Interestingly, we found significant
increases in Tuft cell-related genes including dlck1, IL-25, and
succinate receptor (binding of which with succinate can activate
Tuft cell responses) (50), in virus-infected mice compared to
controls (Figures 4C–E). We also detected significant increases
in the expression of single-stranded RNA-recognizing toll-like
receptors (TLRs) 7 and 8, the IFNα receptor, IFNλ and antiviral
signaling genes including Rig1, Stat1, NFκB, and IFN regulatory
factors (IRF) 1 and 3 in virus+ mice when compared to virus-
mice (Figures 4F–N).We did not observe any significant changes
in the gene expression of tight junction (zonulin and claudin
2), the gut permeability markers; neither antimicrobial peptides
or TLR3, which recognizes double-stranded RNA, between the
two groups (Supplementary Figures 6A–H). Together, our data
suggest that MNV significantly alters the intestinal immune
responses resulting in altered cytokine secretion and activation
of both Tuft cell and antiviral responses.
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FIGURE 4 | Altered intestinal immunity in norovirus infected NOD mice. GF NOD mice were orally gavaged at ∼4 weeks of age with pooled and filtered
norovirus-enriched fecal filtrate from norovirus-infected NOD mice at 12-weeks of age that was UV-treated (virus–) or non-UV-treated (virus+). Only mice gavaged with
the non-UV-treated filtrate were infected with norovirus and developed anti-MNV antibodies. (A) Cytokines in cecal flushes from infected/non-infected mice were
measured by ELISA. (B–N) RNA from the distal small intestine immediately adjacent to the cecum was extracted and equal concentrations of cDNA synthesized.
cDNA was then subject to qPCR for MNV4, genes associated with Tuft cells [doublecortin-like kinase 1 (dclk1), IL25, succinate receptor 1; C–E respectively], with
Toll-like receptor (TLR) genes (tlr7 and tlr8; F,G respectively) and antiviral immune signaling genes [Interferon α receptor 1 (ifnar1), interferon lamda (ifnλ), retinoic
inducible gene I (rigI), signal transducer and activator of transcription 1 (stat1), nuclear factor kappa-light-chain-enhancer of activated B cells (nfκb), interferon
regulatory factor (IRF) 1 and 3; H–M respectively]. The relative expressions of these genes were determined using the 2−11CT method by normalization with GAPDH.
Data were assessed for significance using a Student’s T-test (A–N). Data shown are representative of one of two experiments with n = 4 per group/experiment.
*P < 0.05, **P < 0.01, ***P < 0.001.
MNV4 Infection of GF NOD Mice
Significantly Alters APCs
To further investigate the effect of MNV infection on immune
cells, we focused on the antigen presenting cells (APCs). We
first assessed the effect on mucosal B cells by evaluation of
immunoglobulins in the gut lumen of infected and non-infected
ex-GF mice. Our results revealed significant reductions in the
concentrations of IgG2a and IgG2b subclasses in the intestine
of MNV-infected mice compared to controls (Figure 5A);
however, these changes were not present in the serum of the
same mice (Supplementary Figure 7A). To probe if the mucosal
antibody changes were due to changes of local B cells, we
investigated the phenotype of B cells in PP and PLN. We found
a reduced population of follicular CD21+CD23+ B cells but
an increase in marginal zone CD21+CD23- B cells in the PP of
virally-infected mice compared to the controls (Figures 5B,C
and Supplementary Figure 7B). We also observed significant
reductions in immature IgD+IgM- B cells, while IgD+IgM+
mature B cells were increased in virally-infected mice compared
to the uninfected controls in the PP (Figures 5D,E and
Supplementary Figure 7C). There was a similar trend in the
PLN, although the changes were not statistically significant.
There were no changes in IgD-IgM+ B cells or IgA+ B cells
(Supplementary Figures 7D,E). Next, we investigated the effect
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FIGURE 5 | Altered APC immunity in norovirus infected NOD mice. GF NOD mice were orally gavaged at ∼4 weeks of age with pooled and filtered norovirus-enriched
fecal filtrate from norovirus-infected NOD mice at 12-weeks of age that was UV-treated (virus–) or non-UV-treated (virus+). Only mice gavaged with the
non-UV-treated filtrate were infected with norovirus and developed anti-MNV antibodies. (A) Cecal antibody concentrations were determined by ELISA. (B–G) The
proportion of cell subsets was determined by flow cytometric analysis. (B,C) The proportion of follicular (CD21+CD23+; B) and marginal zone (CD21+CD23-; C) B
cells from the pancreatic lymph nodes (PLN) and Peyer’s patches (PP) were gated from live, single CD19+TCRbeta- cells prior to gating on CD21/CD23. (D,E) The
proportion of naïve (IgD+IgM-) and mature (IgD+IgM+) B cells were gated as in B,C prior to gating on IgD/IgM. (F) The proportion of CXCR3+ macrophages, gated
from live, single CD19-TCRbeta-IAg7(MHCII)+CD11b+CD11c- cells prior to gating on CXCR3. (G) The proportion of CD86+ macrophages gated as in F prior to
gating on CD86. All data were assessed for significance using a Student’s T-test. Data shown are representative of one of two experiments with n = 4 per
group/experiment. *P < 0.05, **P < 0.01, ***P < 0.001.
of MNV infection on other APC populations. Our results
showed the reduction of CXCR3+ macrophages in the PP
but increased in the PLN of virally infected mice compared
to the controls (Figure 5F and Supplementary Figure 8A).
This suggested an enhanced recruitment of macrophages
to the PLN, whereas the macrophage recruitment in PP
was reduced; there were no changes in any other tissues
studied (Supplementary Figure 8B). Interestingly, we observed
significant reductions in CD86+ macrophages in the PLN,
suggesting a reduced ability to activate the T cells in the PLN
(Figure 5G and Supplementary Figure 8C). We did not find
significant differences in CD11b+CD11c+ cells or CD11b-
CD11c+ dendritic cells (Supplementary Figures 8D–G).
Taking together, our data indicate that MNV4 infection
predominantly alters mucosa-associated B cell responses
as well as influences macrophage recruitment and
costimulation locally.
MNV4 Infection of GF NOD Mice
Significantly Alters T Cells
Having identified significant differences in the APCs related
to the viral infection, we asked if MNV infection also affects
T cells. In line with our results in MNV-infected SPF mice,
presented earlier (Figure 2A), we also discovered that MNV
infection of GF mice significantly increased the number of
Tregs in the spleen and PLN of ex-GF mice compared to
the uninfected control ex-GF mice (Figure 6A). Interestingly
the T cells from infected ex-GF mice showed increased
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FIGURE 6 | Altered T cell immunity in norovirus colonized NOD mice. GF NOD mice were orally gavaged at ∼4 weeks of age with pooled and filtered
norovirus-enriched fecal filtrate from norovirus-infected NOD mice at 12-weeks of age that was UV-treated (virus–) or non-UV-treated (virus+). Only mice gavaged with
the non-UV-treated filtrate were infected with norovirus and developed anti-MNV antibodies. (A) The number of CD4+FoxP3+ Tregs were calculated from live single
TCRbeta+CD4+CD8- T cells prior to FoxP3 gating in the spleen and pancreatic lymph node (PLN). (B,C) Cells were stimulated for 4-h in the presence of PMA,
Ionomycin, and Golgi Plug prior to surface and intracellular staining. TNFα-secreting CD4 (B) or CD8 (C) T cells were gated from live single TCRbeta+ cells prior to
CD4 or CD8 gating then subsequent gating on TNFα. Cells shown are from the PLN and Peyer’s patches (PP). (D) The proportion of KLRG1+ CD8T cells gated from
CD19-TCRbeta+CD4-CD8+ T cells prior to gating on KLRG1+ cells in the PLN and PP. (E) Proliferation of BDC2.5 CD4+ T cells to mimotope peptide in the
presence of Tregs (1:2) from virus- or virus+ mice. Background proliferation (APCs + BDC2.5 + Tregs without peptide) was subtracted from proliferation with peptide.
Data are shown as change in counts per minute (1CPM). (F) IFNγ measured by ELISA from Treg suppression culture supernatants in E. All data were assessed for
significance using a Student’s T-test. Data shown are representative of one of two experiments with n = 4 per group/experiment. *P < 0.05, **P < 0.01.
TNFα-secreting CD4 and CD8T cells in the PP and PLN,
respectively (Figures 6B,C and Supplementary Figures 9A,B).
However, we did not observe any significant differences in IL-
10-, IL-17a-, or IFNγ-secreting T cells in either the PP or
PLN (Supplementary Figures 9C–H). We also found increased
proportions of KLRG1-expressing CD8T cells in virus-infected
mice vs. the controls (Figure 6D and Supplementary Figure 9I),
suggesting an increase in the antigen-experienced memory
CD8T cells. To test whether MNV4 infection affected the
function of the Treg cells, we performed antigen-specific
Treg suppression assays. We found that Tregs from MNV4-
infected mice showed significantly greater suppression of the
proliferation of BDC2.5 CD4+ T cells and secretion of IFNγ
upon recognition of the antigenic peptide, compared to the
Tregs from the uninfected controls (Figures 6E,F). Interestingly,
we did not find any differences in IL10 or TGFβ production
in the culture supernatants of the Treg suppression assays
(Supplementary Figures 9J,K). To further confirm that MNV4,
not the altered gut microbiota, was responsible for the Treg
expansion, we colonized GF NOD mice with the gut bacteria
from SPF NOD mice in the presence or absence of MNV4. We
found that only whenMNV4 was present was there an expansion
of Tregs in the PLN and PP (Supplementary Figure 9L). Thus,
our data suggest MNV4 predominantly promotes immune
responses both in the intestinal tissue and the PLN, with
the expansion and enhanced function of Treg cells in
PLN, providing protection against T1D development in the
infected mice.
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MNV4-Containing Fecal Filtrate Modulates
T Cell Response Differently Dependent on
Whether the T Cells Have Previously Been
Exposed to MNV4
To determine the response of immune cells to direct
exposure to MNV4, splenocytes from norovirus+ and
norovirus- ex-GF NOD mice were cultured overnight with
the fecal filtrate collected from the ex-GF norovirus+ mice.
There was minimal T cell activation (determined by CD69
expression) without exposure to the viral positive fecal filtrate
regardless of the source of splenocytes (Figures 7A,B and
Supplementary Figures 10A,B). However, upon exposure
to the virus-positive fecal filtrate, T cells from MNV4 naive
ex-GF mice were highly activated, whereas T cells from MNV4
infected ex-GF mice showed significantly reduced activation
(Figures 7A,B and Supplementary Figures 10A,B). While
we did not observe obvious changes in Tregs, we found that
MNV4 exposure promoted more activation and increased
expression of CTLA4 on Tregs in splenocytes from virus-
naïve ex-GF mice compared to virus-experienced ex-GF
mice (Figures 7C,D and Supplementary Figures 10C–E).
This suggests that MNV could modulate Tregs. Again,
there was no difference in IL-10- secreting CD4T cells
(Supplementary Figure 10F). Direct exposure of splenocytes
to MNV-containing fecal filtrate induced significantly more
IFNγ-secreting CD8T cells and TNFα-secreting CD4 and
CD8T cells, respectively, from cells taken from MNV-
experienced ex-GF mice compared to the cells from naïve
ex-GF mice (Figures 7E–G and Supplementary Figures 10G–J).
Interestingly, direct exposure of MNV-containing fecal filtrate
did not have much effect on macrophages, dendritic cells or
B cells from both MNV-experienced and MNV-naïve ex-GF
mice (Supplementary Figure 11). To determine whether MNV4
infected T cells and/or APCs directly, we assessed MNV4
gene expression in purified splenic T cells and APCs by qPCR.
Interestingly, we found that T cells but not APCs were infected by
MNV4 (Figures 7H,I), suggesting that MNV has direct effect on
T cells. Finally, to confirm whether exposure to MNV4 affected
the Treg recruitment in vivo, we first cultured splenocytes from
MNV4-naïve NOD mice in vitro in the presence or absence
of MNV4 for 12 h, followed by adoptive transfer of the MNV-
exposed T cells into Rag-deficient NOD mice. Treg expansion
was observed in the recipients as early as a week after the transfer
(Figure 7J). These Tregs, specifically in the PLN also expressed
more CD39 (Figure 7K and Supplementary Figure 12A)
when compared to the Tregs from the recipients that were
transferred with non-MNV4-exposed cells. As CD39 positive
Tregs have better suppressive function (51), this may explain
the enhanced Treg suppression (Figure 6E) and protection
from T1D (Figure 1A) observed in our study. Moreover, we
demonstrated that the MNV4-exposed Tregs had increased
expression of CCR6, CCR7, and CCR9, compared to the Tregs
without exposure to MNV4 (Figures 7L–N, respectively, and
Supplementary Figures 12B–D), however, only the increase
in CCR7 expression was restricted to the PLN. This may
suggest these Tregs are preferentially recruited via CCR7
to the pancreatic lymph nodes in response to chemokine
expression (CCL19/CCL21).
DISCUSSION
Viral infections, particularly enteric viruses, have been linked to
the development of T1D (12–15, 18, 20, 43, 52, 53); however,
most of these studies have focused on the coxsackievirus
or rotavirus, little is known the role of norovirus in T1D
development. Using the NOD mouse model of human T1D,
we investigated the effect of noroviral infection on the natural
history of T1D development. We identified four novel findings in
this study. First, unlike the studies in coxsackievirus or rotavirus,
which promote T1D development (17, 54), norovirus infection
protects mice from T1D development. Second, we discovered
that norovirus infection induces an expansion of regulatory
T cells but reduces proinflammatory T cells, specifically in
pancreatic draining lymph nodes, potentially as a direct effect
of viral infection. Third, we found that noroviral infection
alters the composition of gut commensal bacteria in the hosts,
which adds another plausible mechanism for T1D protection.
This is different from an IL-10 deficient IBD mouse model, in
which noroviral infection triggered gut microbiota-driven IBD
development (35). Last but most importantly, we verified our
findings by infection of GF NOD mice, which tested the viral
effect more directly. Using GF mice, we identified that norovirus
infection alters the phenotype of mucosal B cells andmacrophage
and inhibits mucosal IgG2a and IgG2b-producing B cells. Thus,
our study demonstrated that noroviral infection protects NOD
mice from T1D development, and this was associated with the
expansion, recruitment and enhanced function of Treg cells,
more evident in pancreatic draining lymph nodes, alteration of β-
diversity in gut commensal bacteria and reshape mucosal B cells
and macrophages.
Many studies including our own have shown that the gut
microbiota canmodify the immune system in NODmice (2, 5, 8–
11, 38, 40, 44, 55, 56) and the composition of gut microbiota is
altered in individuals with pre-diabetes and human individuals
with T1D (6, 7, 57–59). However, it is not clear if the effects are
directly due to the gut commensal bacteria or enteric viruses,
as many endogenous (bacteriophages) and exogenous (from
the environment) viruses are present in the gut ecosystem.
Furthermore, some enteric viruses are harmless whereas others
are pathogenic, with the latter causing damage to the enterocytes
and alteration of gut microbiota (60). It is also important to
note that the gut microbiota composition can also alter the
susceptibility of the virus to persist. Thus far, most of the studies
in relation to viral infection and T1D development, in mouse
andman, have been focused on the immunopathogenic effect; the
knowledge of immune-regulatory effect of enteric viral infection
is largely unknown. By probing the role of murine norovirus
infection in T1D development in NOD mice, we discovered
that MNV4 infection has beneficial effects in preventing T1D
development in NOD mice. MNV4 infection promotes the
expansion of Treg cells and the suppressive function of Tregs;
and alters the mucosal B cell response. Further, MNV4 infection
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FIGURE 7 | Altered T cell immunity after exposure to MNV4 in vitro. Fecal pellets from MNV4-infected 12-week old GF NOD were homogenized and filtrate was
cultured with splenocytes from MNV4- or MNV4-colonized GF NOD mice. Cells were stimulated for 12 h prior to the addition of PMA, Ionomycin and GolgiPlug for a
further 4 h preceding the surface and intracellular staining. As a control, splenocytes were not stimulated with MNV4-containing fecal filtrate but were stimulated with
PMA, Ionomycin and GolgiPlug. (A,B) The proportion of CD69+ CD4T cells (A) and CD8T cells (B) were gated from live, single TCRbeta+CD19- cells prior to gating
on CD4 or CD8 respectively and then CD69. (C,D) CD4+FoxP3+ Tregs were investigated for CD69+ (C) and CTLA4+ (D) cells. Tregs were gated as in B, prior to
FoxP3 gating and then CD69 or CTLA4 gating. (E–G) The proportion of IFNγ-secreting CD8T cells (E) and TNFα-secreting CD4T cells (F) and CD8T cells (G) were
gated as in A,B prior to subsequent gating on IFNγ or TNFα. RNA from cultured T cells or APCs was isolated following exposure to UV-treated or UV-untreated
(MNV4-containing) fecal material. Equal concentrations of cDNA were synthesized and then subjected to qPCR for MNV4 (H,I). The relative expressions of these
genes were determined using the 2−11CT method by normalization with GAPDH. MNV4-exposed or MNV4-naive splenocytes were adoptively transferred into
Rag-deficient NOD mice (4 × 106/donor). Seven-days later mice were sacrificed and Tregs were investigated by flow cytometric analysis. Tregs were gated from live,
single cell, CD4+TCRbeta+Foxp3+ T cells. Treg number (J) and the proportion of CD39- (K), CCR6- (L), CCR7- (M) and CCR9-expressing (N) Tregs are shown. All
data were analyzed for significance using a Student’s T-test. Data shown are representative of one of two experiments, averaged from experimental duplicates with n
= 4 per group/experiment. *P < 0.05, **P < 0.01, ***p <0.001.
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affected the overall richness of the gut bacteria and changed
the β-diversity of the gut commensal bacteria. To distinguish
virus-dependent gut commensal bacterial effects, we took a
novel approach using GF NOD mice and reconstitute with a
fecal filtrate preparation with or without norovirus, from which
gut bacteria were removed. With this approach in GF mice,
we are able to better identify the immune responses directly
related to the noroviral infection. Importantly, we were able
to recapitulate Treg expansion in infected ex-GF mice. Using
a DSS induced colitis model, Kernbauer et al. showed that
MNV infection replaced the immune-beneficial function of gut
microbiota mediated by group 2 innate lymphoid cells (ILC2)
and type 1 interferon signaling (61). Similarly, we found an
increased gene expression of IL-25 in response to norovirus
infection, which has been reported to induce and regulate ILC2
cells (62). We also found increased IL-4 in the intestinal wash
of norovirus–infected mice, suggesting that there may be a role
for IL-4-producing ILC2s in mediating some of the intestinal
changes observed in our study. Although we did not find obvious
changes in IL-5, IL-13, or Th2 cell markers, which are associated
with ILC2 (62, 63), we did, however, observe changes in both the
maturity of B cells and the proportion of follicular B cells in the
PP, accompanied with alterations of IgG2 antibody production
in the gut lumen but not in the circulation. Moreover, our
results also demonstrated elevated soluble IFNα in the gut lumen
and highly up-regulated genes encoded for IFNα receptor and
Stat-1 (33) in the intestine tissue of norovirus infected ex-GF
mice. This suggests that the norovirus induces a stronger local
immune response.
It has recently reported that a strain of norovirus infects Tuft
cells in the intestine (49). To determine whether MNV4 was
present in IECs, we determined MNV4 gene expression by qPCR
from isolated IECs of ex-GF mice. We found that MNV4 was
highly expressed in the infected mice, suggesting that MNV4 can
infect IECs. To investigate ifMNV4 infection affects Tuft cells, we
evaluated the Tuft cell markers (49) in the distal small intestine,
by qPCR. We found enhanced expression of Tuft-cell related
genes in our MNV4 infected mice, supporting the interactions
of MNV-Tuft cell/IEC. It should be noted, however, that the
tropism for MNV4 is not yet known, therefore, whether MNV4
directly infects Tuft cells, as does CR6 (49), or if the Tuft cells are
indirectly affected by MNV4 infection remains to be determined.
In addition to Tuft cells, gut epithelial cells express an array of
Toll-like receptors (TLRs). Noroviruses are single-stranded RNA
(ssRNA) viruses and TLR7 and TLR8 are the receptors for ssRNA.
Not surprisingly, both genes encoding TLR7 and TLR8 are highly
up-regulated in the small intestinal tissue of the virally-infected
ex-GF mice. Interestingly, gene expression of RIG-I, the receptor
for double-stranded RNA (dsRNA), was also significantly up-
regulated in the same tissue from the norovirus infected mice. It
is possible that dsRNAs are derived from either replicating viral
genomes or self-RNAs released upon either infection-mediated
cell lysis or the physiological turnover of gut epithelial cells or a
combination of all of the above.
As insulin-producing β-cell destruction is T cell mediated
in T1D, norovirus infection will most likely impact the T
cells directly or indirectly to affect the disease susceptibility.
It is intriguing that MNV4 infection promotes the expansion
of regulatory T cells in vivo, which in turn can suppress
the ongoing β-cell destruction and prevent the mice from
T1D development. This is supported by the reduction of
proinflammatory cytokine-secreting T cells in the PLN of the
infected mice. Interestingly, direct exposure of norovirus+ fecal
material to splenocytes from naïve ex-GF mice resulted in a
higher proportion of activated Tregs and increased CTLA-4
expression on Tregs, whereas the direct exposure of splenocytes
from virally-experienced ex-GF mice to norovirus+ fecal filtrate
induced fewer activated Tregs but more inflammatory T
cells. We also observed that MNV4-exposed Tregs, following
adoptive transfer into Rag-deficient NODmice, expressed higher
CD39 and were preferentially recruited to the PLN. This
suggests that primary norovirus infection promotes an immune
suppressive stage whereas secondary or persistent infection
could lead to an inflammatory state. This may partially explain
the rise of diabetes development after 20-weeks of age in
the infected NOD mice as MNV4 actively replicates in the
infected mice.
In our study we infected mice at ∼4 weeks of age, leading to
diabetes protection. It is possible that the age of the mice may
influence either the ability of norovirus to modulate the immune
system to promote tolerance over diabetogenicity or the type of
host immune response to noroviral infection or both. In rotavirus
studies, Graham et al. found that rotaviral infection in young
NODmice led to diabetes protection while infection in adulthood
accelerated the development of T1D (16, 17). We will test this
possibility in the future studies.
It is important to note that norovirus is a common mouse
pathogen in animal facilities, causing persistent infections (64).
Eradication of MNV from animal facilities requires rederivation
in addition to strict observance of stringent standard operating
protocols (65–67). Our study shows that MNV can protect
NOD mice from developing T1D; however, it is possible that
MNV infection may result in negative effects in different disease
models using different mouse strains. Thus, it is recommended
that more specific pathogens should be tested and reported in
research studies.
In summary, our findings demonstrate that norovirus
infection promoted protection from T1D development in NOD
mice by increasing the number of Tregs, increasing intestinal
immunity (including Tuft cells), changing the composition of
gut commensal bacteria and local immune cell phenotype and
function. Given the high virulence of norovirus in humans, it is
likely to be encountered by individuals at risk of developing T1D,
particularly as children are more susceptible. Our study not only
highlights the importance of virus-commensal bacteria-immune
interactions in T1D but also suggests that some enteric viral
infections may be beneficial in preventing autoimmune disease
such as type 1 diabetes.
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